We love to see it! Congratulations to Dr Matthew Summers, Dr Paul Lavigne, and the team at Sentara Health in Norfolk, VA on treating your 1st single arm patient in the COSIRA-II study. The right-side reversible ischemia single arm patient received #ShockwaveReducer with the goal of providing relief for their refractory angina. To learn more about the #COSIRAII trial and for a list of participating sites visit http://clinicaltrials.gov ISI http://bit.ly/3iEq7fC Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
Shockwave Medical’s Post
More Relevant Posts
-
Worldwide Medical Affairs Professional: Focused on Gene Therapy, Rare Diseases, Neurology, LATAM Liaison, Movement Disorders, Immunology, Innovation, Strategy, Change Mgmt, Product Launch, Project Mgmt and Product Mgmt
So proud to be making headway with the positive opinion today from CHMP. Keeping our mission of always putting patients first!! #curefa #medicalaffairs #datascience #biopharma #pharmaceuticals #drugdevelopment #neurology #neuroscience #ataxia #FriedreichsAtaxia #friedreichsataxianews #livingwithfriedreichsataxia #livingwithFA #biogen
We’ve received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for our Friedreich’s ataxia (FA) therapy in people aged 16 years and older. If approved, this will be the first therapy in the European Union to treat FA. This is a significant milestone as we work toward our goal of bringing a meaningful treatment to the FA patient community in the region. Read more here: https://ow.ly/ntvg50QjanS #Ataxia | #FriedreichsAtaxia
-
-
M.D., Ph.D. of Traditional Persian Medicine. Graduated from Tehran University of Medical Sciences
The effect of a topical formulation from Lawsonia inermis L. (henna) on pain intensity in patients with chronic sciatica: A randomized double-blind clinical trial Henna oil seems to be an effective treatment to reduce pain intensity in patients with chronic sciatica. Moreover, it improves quality of life and functional ability. Further randomized controlled trials with longer intervention periods are recommended to confirm this efficacy. https://lnkd.in/d8XyE6uJ #sciatica #sciaticarelief #pain #henna #herbs #herbalmedicine #plants Authors: Narges Lavari, Nima Ostadrahimi, Roja Rahimi, mehdi raei, Alireza Abbassian
-
-
Pharmacist. Consultant. Immunizer. Educator. Entrepreneur. Mentor. Healthcare Advocate.
Exploring the profound insights on the design of psychedelic-assisted healing. This video sheds light on the perspectives of the indigenous community, emphasizing the sacred and traditional use of plant medicines. A crucial reminder to consider all voices in this transformative journey. #PsychedelicHealing #IndigenousWisdom Video Link: https://lnkd.in/gnCuJJJ2 Or check out the link in the original post
Medicine Woman | Transpersonal Psychotherapist | Transformational Speaker | Global Wellness Consultant | Spiritual Guide for Revolutionary Leaders
Vital conversation about sacred reciprocity and right relationship when it comes to psychedelic medicines. Thank you Ariel Clark for sharing.🙏🏽 https://lnkd.in/eZSak6Gf
-
Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments At over 5,000 words, this policy-focused Psychedelic Bulletin dives deep into a number of recent events including inaugural hearings in the U.S. House, subcommittee meetings and forums, as well as the publication of reports and key changes to major psychedelic policy reform efforts. This issue’s contents: - California: TREAT Retreats and Wiener Regroups, While Psilocybin Decrim. Initiative Continues Collecting Signatures - Veterans’ Affairs Subcommittee on Health Discusses Psychedelics - Canadian Senate’s Subcommittee on Veterans Affairs: “The Time is Now” to Fund Psychedelic-Assisted Therapy Research - Transform Drug Policy Foundation Publishes a “Practical Guide” to Regulating Psychedelics UK Government Responds to Drugs Committee’s Report - More Policy News The next Issue will focus on psychedelic business news and analysis, from fundraising through to drug development milestones. https://lnkd.in/gQYHPp6s
-
Curious whether endobronchial valves can help your severe #COPD/#emphysema patients? Read the consistent clinical findings from four randomized controlled trials on the Zephyr Valves. https://bit.ly/46YYmWe #Pulmonary #Pulmonology #MedTech #LungHealth #COPDSupport
-
-
In their clinical report, Wong et al. aimed to assess a novel dermal cooling system (DCS) for reducing pigmentation in benign lesions among Asian patients and its associated side effects. This prospective, single-center study included patients with various benign pigmented lesions... To read the full article, visit https://lnkd.in/gdNrDZbC Enjoy free access to this Editor’s Choice article. ASLMS members receive full access to all journal articles. Not a member? Visit aslms.org to learn more about becoming an ASLMS member today! #aslms #LasersinSurgeryandMedicine #EditorsChoice #Asians #benignpigmentedlesions #controlledcooling #dermalcoolingsystem
-
-
📰 Groundbreaking findings from LIFE-BTK now in the New England Journal of Medicine show: Esprit™ BTK drug-eluting resorbable scaffold demonstrated superior results vs angioplasty with respect to the primary efficacy endpoint among patients with #CLTI due to infrapopliteal disease. https://lnkd.in/gu7rAmZi Caution: Esprit™ BTK is an Investigational Device. Limited by Federal (USA) law for investigational use only. #ClinicalTrials #CLTI #PeripheralArteryDisease #Angioplasty
-
-
Consultant cardiologist and electrophysiologist Fields of interest: EP & Heart Failure
What is your anticoagulation management strategy after Cardioversion in Patients with LAAO? Do you just continue the current regime (Aspirin alone or whatever the patient has), or fully anticoagulate for four weeks due to LA stunning? We typically anticoagulate for four weeks to prevent thrombus formation in the left atrium, despite the occluder, because we encountered a case of large LA-thrombae 3 weeks after cardioversion, but a thorough literature review revealed no data on this issue.
-
When a study does not meet our expectations … Was teriflunomide the right comparator considering the fact that there is evidence that teriflunomide may influence microglial activation? Looking forward to the results of the other phase III trials. #multiplesclerosis #MS #BTK #neurology #microglia # imeldaziekenhuis
Evobrutinib is no better than teriflunomide. The EVOLUTION phase 3 clinical trials showed evobrutinib did not meet its primary endpoint of annualised relapse rate for up to 156 weeks compared to oral teriflunomide. Why? What does this mean for the BTKi's? https://buff.ly/46Fggfa
-
-
FRFEEFIX® Ulnar Shortening System - The freedom to perform a distal or proximal osteotomy based on clinical need. https://lnkd.in/eg6Jh9se
